Showing results filtered by:
32 Results
World Malaria Day is an opportunity to reflect on continuing challenges posed by malaria and reaffirm a commitment to overcoming them. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, joins with the global health community in recognizing this year’s theme of “Time to Deliver on Zero Malaria: Invest, Innovate, Implement.”
Published: April 25, 2023
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), reaffirms our commitment to developing safe and effective medical tools against malaria, and, in the words of this year’s World Malaria Day theme, “Harnessing innovation to reducing the malaria disease burden and saving lives.”
Published: April 25, 2022
The Apicomplexan Molecular Physiology Section (AMPS) studies the cell and molecular biology of malaria parasites. We are focused on ion channels and transporters unique to these parasites and aim to develop novel antimalarial therapies against these targets.
Last Reviewed: September 29, 2022
Identifying components and determining mechanisms involved in transcription of herpes simplex virus (HSV) genes during the initiation of lytic infection and during viral reactivation from latency. This includes the integration of transcription factors, coactivators, epigenetic machinery, and transcription elongation factors that impact the expression of the first wave of viral genes.
Last Reviewed: September 21, 2022
An integrated program investigating mast cell biology includes studies into growth & differentiation of mast cells, mast-cell signal transduction, & products generated by mast cells that lead to disease. MCBS emphasizes basic research that may be translated to the clinic & the bench. Protocols include studies on the pathogenesis of anaphylaxis, physical urticarias & clonal mast cell disorders.
Last Reviewed: October 6, 2022
A NIAID-supported Phase 3 clinical trial evaluating an investigational COVID-19 vaccine called AZD1222 will enroll around 30,000 adult volunteers.
Published: August 31, 2020
A fourth Phase 3 NIH clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.
Published: September 23, 2020